Key Insights

Highlights

Success Rate

88% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

3.7%

1 terminated out of 27 trials

Success Rate

87.5%

+1.0% vs benchmark

Late-Stage Pipeline

4%

1 trials in Phase 3/4

Results Transparency

0%

0 of 7 completed with results

Key Signals

88% success

Data Visualizations

Phase Distribution

21Total
Not Applicable (15)
Early P 1 (1)
P 1 (2)
P 2 (2)
P 4 (1)

Trial Status

Recruiting12
Completed7
Active Not Recruiting3
Not Yet Recruiting3
Suspended1
Terminated1

Trial Success Rate

87.5%

Benchmark: 86.5%

Based on 7 completed trials

Clinical Trials (27)

Showing 20 of 20 trials
NCT06864936Not ApplicableRecruitingPrimary

Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis

NCT07222956Phase 2Not Yet RecruitingPrimary

A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS

NCT07230015Not ApplicableRecruitingPrimary

Combined Motor Imagery and Vestibular Rehab for MS

NCT07545889Not ApplicableNot Yet Recruiting

Multicenter Prospective Study Analyzing the Occurrence of Multiple Sclerosis Relapses Without Radiological Evidence: Myth or Reality?

NCT07501520Not ApplicableCompletedPrimary

Effect of Low Histamine-Based Modified Mediterranean Diet in Multiple Sclerosis

NCT07292480Not ApplicableRecruitingPrimary

Monthly Monitoring of Plasma NfL in Treated Relapsing-remitting Multiple Sclerosis to Detect Persistent Infraclinical Disease Activity

NCT06884579Not ApplicableActive Not RecruitingPrimary

Educational Programs Based on Healthy Habits to Improve Quality of Life and Psychosocial Profile in Women With Neurodegenerative Diseases: the ADVICE Protocol Study (Phase 2)

NCT06925022Not ApplicableActive Not RecruitingPrimary

Educational Programs Based on Healthy Habits to Improve Quality of Life and Psychosocial Profile in Women With Neurodegenerative Diseases: The ADVICE Protocol Study (Phase 1)

NCT07225361Phase 4Recruiting

Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis

NCT07376772Not ApplicableRecruitingPrimary

Wearable Focal Vibration Therapy on Upper Extremity Function of People With Multiple Sclerosis: A Pilot Study

NCT06629428Early Phase 1RecruitingPrimary

Effects of Ublituximab on Motor Functions in Multiple Sclerosis

NCT07360977Not ApplicableRecruiting

Myrosinase Bioactivated Gglucoraphanin for the Treatment of Neurodegenerative Diseases (GRA-MYR-ND)

NCT07233902Not ApplicableCompleted

MS Synchronous vs Asynchronous Exercise Study

NCT07355387Not ApplicableRecruiting

Home Based Functional Balance Intervention for Multiple Sclerosis

NCT07273604Not ApplicableCompletedPrimary

Psychological Interventions for Multiple Sclerosis: Effects on Anxiety, Depression, and Cognition.

NCT07235644Active Not Recruiting

Comparison of Efficacy and Safety in Patients Switching From MabThera® to Rixathon® in Relapsing-Remitting Multiple Sclerosis

NCT07222618Recruiting

"Selfie" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS

NCT07006805Phase 1Not Yet Recruiting

RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis

NCT07193823Recruiting

Sexual Dysfunction in Women With Multiple Sclerosis (MS)

NCT04031469Suspended

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

Scroll to load more

Research Network

Activity Timeline